Loading…
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $89M | $-50M | $-53M | $-42M | -34.4% | 36.1% | 32.0% |
| 2024 | $65M | $-37M | $-40M | $-36M | -21.2% | 44.7% | 37.3% |
| 2023 | $45M | $-27M | $-29M | $-30M | 26.2% | 74.5% | -20.7% |
| 2022 | $26M | $-35M | $-37M | $-33M | 43.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 25.92 | 45.22 | 65.44 | 89.06 |
| Operating Revenue | 25.92 | 45.22 | 65.44 | 89.06 |
| Cost Of Revenue | 4.43 | 7.06 | 8.69 | 10.79 |
| Gross Profit | 21.49 | 38.16 | 56.75 | 78.27 |
| Operating Expense | 57.51 | 68.20 | 96.46 | 136.68 |
| Research And Development | 7.24 | 8.99 | 13.56 | 19.14 |
| Selling General And Administration | 50.27 | 59.21 | 82.90 | 117.53 |
| Total Expenses | 61.94 | 75.27 | 105.15 | 147.46 |
| Operating Income | -36.02 | -30.04 | -39.71 | -58.40 |
| Total Operating Income As Reported | -36.02 | -30.04 | -39.71 | -58.40 |
| EBITDA | -35.06 | -26.51 | -37.32 | -50.18 |
| Normalized EBITDA | -34.89 | -26.56 | -35.83 | -50.18 |
| EBIT | -35.56 | -27.36 | -38.46 | -51.52 |
| Interest Expense | 1.60 | 2.10 | 1.99 | 1.89 |
| Net Interest Income | -1.60 | -2.10 | -1.99 | -1.89 |
| Other Non Operating Income Expenses | 0.64 | 2.64 | 2.74 | 6.88 |
| Other Income Expense | 0.46 | 2.69 | 1.25 | 6.88 |
| Interest Expense Non Operating | 1.60 | 2.10 | 1.99 | 1.89 |
| Net Non Operating Interest Income Expense | -1.60 | -2.10 | -1.99 | -1.89 |
| Pretax Income | -37.16 | -29.45 | -40.46 | -53.41 |
| Tax Provision | 0 | 0.01 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -37.16 | -29.46 | -40.46 | -53.41 |
| Net Income From Continuing And Discontinued Operation | -37.16 | -29.46 | -40.46 | -53.41 |
| Net Income From Continuing Operation Net Minority Interest | -37.16 | -29.46 | -40.46 | -53.41 |
| Net Income | -37.16 | -29.46 | -40.46 | -53.41 |
| Net Income Common Stockholders | -37.16 | -29.46 | -40.46 | -53.41 |
| Net Income Including Noncontrolling Interests | -37.16 | -29.46 | -40.46 | -53.41 |
| Normalized Income | -36.99 | -29.51 | -38.96 | -53.41 |
| Diluted NI Availto Com Stockholders | -37.16 | -29.46 | -40.46 | -53.41 |
| Basic Average Shares | 23.32 | 23.32 | 11.95 | - |
| Diluted Average Shares | 23.32 | 23.32 | 11.95 | - |
| Reconciled Depreciation | 0.50 | 0.85 | 1.14 | 1.34 |
| Reconciled Cost Of Revenue | 4.43 | 7.06 | 8.69 | 10.79 |
| Total Unusual Items | -0.18 | 0.05 | -1.50 | - |
| Total Unusual Items Excluding Goodwill | -0.18 | 0.05 | -1.50 | - |
| Gain On Sale Of Security | -0.18 | 0.05 | -1.50 | - |
| General And Administrative Expense | 18.46 | 20.29 | 33.84 | 44.45 |
| Other Gand A | 18.46 | 20.29 | 33.84 | 44.45 |
| Selling And Marketing Expense | 31.81 | 38.92 | 49.06 | 73.08 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| CBLLthis co. | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 | 5.2% | 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Solid Biosciences Inc. | SLDB | $713M | -4.09 | 3.96 |
| -96.8% |
| -3.80 |
| Enhabit, Inc. | EHAB | $707M | -153.68 | 1.32 | -0.9% | 20.09 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Aura Biosciences, Inc. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Peer Median | - | -12.20 | 3.18 | -40.1% | -5.03 | |